Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3671638 | 0.77 | MEN1 (0.43) | — | |
| Hydrochloric Acid SCHEMBL5245496 | 0.75 | PDE10A (0.48) | — | |
| SCHEMBL12861090 | 0.72 | SRC (0.32) | — | |
| SCHEMBL10653163 | 0.65 | MEN1 (0.44) | ESR2ESR1 | |
| SCHEMBL21259084 | 0.65 | ESR2 (0.39) | ESR2ESR1 | |
| SCHEMBL14221637 | 0.62 | PDE10A (0.38) | — | |
| SCHEMBL8967395 | 0.61 | MEN1 (0.35) | ESR2ESR1 | |
| SCHEMBL14975984 | 0.61 | RAD52 (0.40) | ESR2ESR1 | |
| SCHEMBL27455753 | 0.60 | PTPN1 (0.38) | ESR2ESR1 | |
| SCHEMBL20006648 | 0.59 | CSNK2A1 (0.42) | ESR2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1802585-A1 | 4-SUBSTITUTED 4,6-DIALKOXY-CINNOLINE DERIVATIVES AS PHOSPODIESTERASE 10 INHIBITORS FOR THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL SYNDROMS | Memory Pharmaceuticals Corporation (US) | 2007-07-04 | — | — | EP | claimed |
| US-20060160814-A1 | Phosphodiesterase 10 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2006-07-20 | — | — | US | claimed |
| WO-2006028957-A1 | 4-SUBSTITUTED 4, 6-DIALKOXY-CINNOLINE DERIVATIVES AS PHOSPODIESTERASE 10 INHIBITORS FOR THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL SYNDROMS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2006-03-16 | — | — | WO | claimed |
| EP-1802585-A1 | 4-SUBSTITUTED 4,6-DIALKOXY-CINNOLINE DERIVATIVES AS PHOSPODIESTERASE 10 INHIBITORS FOR THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL SYNDROMS | Memory Pharmaceuticals Corporation (US) | 2007-07-04 | — | — | EP | disclosed |
| US-20060160814-A1 | Phosphodiesterase 10 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2006-07-20 | — | — | US | disclosed |
| WO-2006028957-A1 | 4-SUBSTITUTED 4, 6-DIALKOXY-CINNOLINE DERIVATIVES AS PHOSPODIESTERASE 10 INHIBITORS FOR THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL SYNDROMS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160814-A1 | Phosphodiesterase 10 inhibitors | PDE5A, PDE3A, PDE2A | ESR2 3561/4885ESR1 3543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.